-
For Rare Neural Diseases, Is Ovid Therapeutics The Right Team At The Right Time?
Tuesday, May 30, 2017 - 2:17pm | 390Read More...The Cowen Group has initiated coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with an Outperform rating and $14.48 price target. It's Time To Tackle Orphan Neurological Disorders Until now, the biopharmaceutical industry has mostly ignored orphan neurological disorders due to the difficulty of...
-
Report: Valeant Rejected A Takeover Offer Prior To Hiring Papa As CEO
Friday, May 27, 2016 - 9:39am | 251Read More...The Wall Street Journal reported late Thursday afternoon that prior to hiring Joseph Papa as CEO, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) received an acquisition proposal from Japan's Takeda Pharmaceutical and private equity firm TPG. The Wall Street Journal, citing "people familiar with the...
-
Orexigen Up, Then Steeply Down Following Contrave U.S. Rights Agreement
Tuesday, March 15, 2016 - 12:10pm | 274Read More...Orexigen Therapeutics, Inc. (NASDAQ: OREX) spiked almost 3 percent to $0.81 early Tuesday, but quickly plummeted more than 6 percent. The volatility comes on back of news that the pharmaceutical company will be acquiring Contrave®, the "market leading national branded prescription...
-
No Legwork Mondays – Takeda, Eli Lilly And Actos
Monday, April 21, 2014 - 10:33am | 454Read More...Most people have seen advertisements which extol a drug's benefits while simultaneously warning of its potential side effects. Comedians often point out that the side effects can seem worse than conditions the drug addresses. More important, however, the warnings can foreshadow larger...
